WO2008027558A2
(en)
|
2006-08-31 |
2008-03-06 |
Codon Devices, Inc. |
Iterative nucleic acid assembly using activation of vector-encoded traits
|
CN103502448B
(zh)
|
2010-11-12 |
2017-03-29 |
Gen9股份有限公司 |
核酸合成的方法和设备
|
US10457935B2
(en)
|
2010-11-12 |
2019-10-29 |
Gen9, Inc. |
Protein arrays and methods of using and making the same
|
WO2016100976A2
(en)
*
|
2014-12-19 |
2016-06-23 |
Apprise Bio, Inc. |
Methods for identifying multiple epitopes in selected sub-populations of cells
|
US11560585B2
(en)
|
2011-01-31 |
2023-01-24 |
Roche Sequencing Solutions, Inc. |
Methods of identifying multiple epitopes in cells
|
US10144950B2
(en)
|
2011-01-31 |
2018-12-04 |
Roche Sequencing Solutions, Inc. |
Methods of identifying multiple epitopes in cells
|
EP3613852A3
(en)
|
2011-07-22 |
2020-04-22 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
LT2944693T
(lt)
|
2011-08-26 |
2019-08-26 |
Gen9, Inc. |
Kompozicijos ir būdai, skirti nukleorūgščių didelio tikslumo sąrankai
|
US11021737B2
(en)
|
2011-12-22 |
2021-06-01 |
President And Fellows Of Harvard College |
Compositions and methods for analyte detection
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
US9637739B2
(en)
|
2012-03-20 |
2017-05-02 |
Vilnius University |
RNA-directed DNA cleavage by the Cas9-crRNA complex
|
US9150853B2
(en)
|
2012-03-21 |
2015-10-06 |
Gen9, Inc. |
Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
|
LT2841601T
(lt)
|
2012-04-24 |
2019-07-10 |
Gen9, Inc. |
Nukleorūgščių rūšiavimo būdai ir multipleksinis preparatyvinis in vitro klonavimas
|
WO2013163394A1
(en)
|
2012-04-25 |
2013-10-31 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated targeting with large targeting vectors
|
DK3401400T3
(da)
|
2012-05-25 |
2019-06-03 |
Univ California |
Fremgangsmåder og sammensætninger til rna-styret mål-dna-modifikation og til rna-styret transskriptionsmodulering
|
CA2877290A1
(en)
|
2012-06-19 |
2013-12-27 |
Daniel F. Voytas |
Gene targeting in plants using dna viruses
|
EP3483311A1
(en)
|
2012-06-25 |
2019-05-15 |
Gen9, Inc. |
Methods for nucleic acid assembly and high throughput sequencing
|
CN110643600A
(zh)
|
2012-10-23 |
2020-01-03 |
基因工具股份有限公司 |
用于切割靶dna的系统及其用途
|
JP6620018B2
(ja)
|
2012-12-06 |
2019-12-11 |
シグマ−アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニーSigma−Aldrich Co., LLC |
Crisprに基づくゲノム修飾および制御
|
MX2015007550A
(es)
|
2012-12-12 |
2017-02-02 |
Broad Inst Inc |
Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
|
US8993233B2
(en)
|
2012-12-12 |
2015-03-31 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
|
CN105658796B
(zh)
|
2012-12-12 |
2021-10-26 |
布罗德研究所有限公司 |
用于序列操纵的crispr-cas组分系统、方法以及组合物
|
US20140186843A1
(en)
|
2012-12-12 |
2014-07-03 |
Massachusetts Institute Of Technology |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
PT2898075E
(pt)
|
2012-12-12 |
2016-06-16 |
Harvard College |
Manipulação e otimização de sistemas, métodos e composições de enzima melhorados para manipulação de sequências
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
PT2896697E
(pt)
|
2012-12-12 |
2015-12-31 |
Massachusetts Inst Technology |
Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências
|
WO2014093694A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
|
EP3553174A1
(en)
|
2012-12-17 |
2019-10-16 |
President and Fellows of Harvard College |
Rna-guided human genome engineering
|
CN113005148A
(zh)
|
2013-01-16 |
2021-06-22 |
爱默蕾大学 |
Cas9-核酸复合物及其相关用途
|
CN109913495B
(zh)
|
2013-02-20 |
2022-11-25 |
瑞泽恩制药公司 |
大鼠的遗传修饰
|
US10138509B2
(en)
|
2013-03-12 |
2018-11-27 |
President And Fellows Of Harvard College |
Method for generating a three-dimensional nucleic acid containing matrix
|
EP2971167B1
(en)
|
2013-03-14 |
2019-07-31 |
Caribou Biosciences, Inc. |
Compositions and methods of nucleic acid-targeting nucleic acids
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
CA2907198C
(en)
*
|
2013-03-15 |
2019-12-10 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
CA2906747A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Regents Of The University Of Minnesota |
Engineering plant genomes using crispr/cas systems
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
US20140273230A1
(en)
*
|
2013-03-15 |
2014-09-18 |
Sigma-Aldrich Co., Llc |
Crispr-based genome modification and regulation
|
CN105518146B
(zh)
|
2013-04-04 |
2022-07-15 |
哈佛学院校长同事会 |
利用CRISPR/Cas系统的基因组编辑的治疗性用途
|
CN111500630A
(zh)
|
2013-04-16 |
2020-08-07 |
瑞泽恩制药公司 |
大鼠基因组的靶向修饰
|
CN116083487A
(zh)
|
2013-05-15 |
2023-05-09 |
桑格摩生物治疗股份有限公司 |
用于治疗遗传病状的方法和组合物
|
US9873907B2
(en)
|
2013-05-29 |
2018-01-23 |
Agilent Technologies, Inc. |
Method for fragmenting genomic DNA using CAS9
|
US20140356956A1
(en)
*
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
KR102282990B1
(ko)
|
2013-06-04 |
2021-07-28 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Rna-가이드된 전사 조절
|
AU2014281028B2
(en)
|
2013-06-17 |
2020-09-10 |
Massachusetts Institute Of Technology |
Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
|
EP4245853A3
(en)
|
2013-06-17 |
2023-10-18 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
EP3011029B1
(en)
|
2013-06-17 |
2019-12-11 |
The Broad Institute, Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
JP6702858B2
(ja)
|
2013-06-17 |
2020-06-03 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
ウイルス成分を使用して障害および疾患をターゲティングするためのCRISPR−Cas系および組成物の送達、使用および治療上の適用
|
JP2016528890A
(ja)
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
CRISPR/Cas系を用いるゲノム編集の治療用の使用
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
US20150044772A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
Crispr/cas system-based novel fusion protein and its applications in genome editing
|
WO2015026887A1
(en)
|
2013-08-22 |
2015-02-26 |
E. I. Du Pont De Nemours And Company |
A soybean u6 polymerase iii promoter and methods of use
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
AU2014312123A1
(en)
|
2013-08-29 |
2016-03-17 |
Temple University Of The Commonwealth System Of Higher Education |
Methods and compositions for RNA-guided treatment of HIV infection
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
ES2681622T3
(es)
|
2013-09-18 |
2018-09-14 |
Kymab Limited |
Métodos, células y organismos
|
ES2881473T3
(es)
*
|
2013-10-17 |
2021-11-29 |
Sangamo Therapeutics Inc |
Métodos de suministro y composiciones para la modificación por ingeniería genética del genoma mediada por nucleasas
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
WO2015066119A1
(en)
|
2013-10-30 |
2015-05-07 |
North Carolina State University |
Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
|
US9834791B2
(en)
|
2013-11-07 |
2017-12-05 |
Editas Medicine, Inc. |
CRISPR-related methods and compositions with governing gRNAS
|
US10787684B2
(en)
*
|
2013-11-19 |
2020-09-29 |
President And Fellows Of Harvard College |
Large gene excision and insertion
|
US9546384B2
(en)
|
2013-12-11 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a mouse genome
|
RS58159B1
(sr)
|
2013-12-11 |
2019-03-29 |
Regeneron Pharma |
Postupci i kompozicije za ciljanu modifikaciju genoma
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
CN105899657A
(zh)
|
2013-12-12 |
2016-08-24 |
布罗德研究所有限公司 |
用于改变基因产物表达的crispr-cas系统和方法、结构信息以及诱导型模块化cas酶
|
SG10201804973TA
(en)
|
2013-12-12 |
2018-07-30 |
Broad Inst Inc |
Compositions and Methods of Use of Crispr-Cas Systems in Nucleotide Repeat Disorders
|
US9068179B1
(en)
|
2013-12-12 |
2015-06-30 |
President And Fellows Of Harvard College |
Methods for correcting presenilin point mutations
|
CN111206032A
(zh)
|
2013-12-12 |
2020-05-29 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
EP3080271B1
(en)
|
2013-12-12 |
2020-02-12 |
The Broad Institute, Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
MX2016010285A
(es)
|
2014-02-11 |
2017-01-11 |
Univ Colorado Regents |
Ingenieria genetica multiplexada habilitada por crispr.
|
WO2015134812A1
(en)
|
2014-03-05 |
2015-09-11 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
DK3116997T3
(da)
|
2014-03-10 |
2019-08-19 |
Editas Medicine Inc |
Crispr/cas-relaterede fremgangsmåder og sammensætninger til behandling af lebers kongenitale amaurose 10 (lca10)
|
US11242525B2
(en)
|
2014-03-26 |
2022-02-08 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating sickle cell disease
|
CN106460003A
(zh)
|
2014-04-08 |
2017-02-22 |
北卡罗来纳州立大学 |
用于使用crispr相关基因rna引导阻遏转录的方法和组合物
|
BR112016028023A2
(pt)
|
2014-05-30 |
2017-08-22 |
Univ Leland Stanford Junior |
Composições e métodos de administração de tratamentos para infecções virais latentes
|
CN113215196A
(zh)
|
2014-06-06 |
2021-08-06 |
瑞泽恩制药公司 |
用于修饰所靶向基因座的方法和组合物
|
SI3354732T1
(sl)
|
2014-06-23 |
2020-07-31 |
Regeneron Pharmaceuticals, Inc. |
Z nukleazo posredovan DNA sklop
|
HUE041584T2
(hu)
|
2014-06-26 |
2019-05-28 |
Regeneron Pharma |
Célzott genetikai módosítások és alkalmazási módszerek és készítmények
|
US10676754B2
(en)
|
2014-07-11 |
2020-06-09 |
E I Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
EP3169776A4
(en)
*
|
2014-07-14 |
2018-07-04 |
The Regents of The University of California |
Crispr/cas transcriptional modulation
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
CA2958292A1
(en)
|
2014-08-19 |
2016-02-25 |
President And Fellows Of Harvard College |
Rna-guided systems for probing and mapping of nucleic acids
|
NZ728437A
(en)
*
|
2014-08-27 |
2018-02-23 |
Caribou Biosciences Inc |
Methods for increasing cas9-mediated engineering efficiency
|
US10450584B2
(en)
|
2014-08-28 |
2019-10-22 |
North Carolina State University |
Cas9 proteins and guiding features for DNA targeting and genome editing
|
WO2016036754A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification
|
WO2016040594A1
(en)
*
|
2014-09-10 |
2016-03-17 |
The Regents Of The University Of California |
Reconstruction of ancestral cells by enzymatic recording
|
CN108064129A
(zh)
|
2014-09-12 |
2018-05-22 |
纳幕尔杜邦公司 |
玉米和大豆中复合性状基因座的位点特异性整合位点的产生和使用方法
|
EP3204513A2
(en)
*
|
2014-10-09 |
2017-08-16 |
Life Technologies Corporation |
Crispr oligonucleotides and gene editing
|
WO2016061374A1
(en)
|
2014-10-15 |
2016-04-21 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for generating or maintaining pluripotent cells
|
WO2016065364A1
(en)
*
|
2014-10-24 |
2016-04-28 |
Life Technologies Corporation |
Compositions and methods for enhancing homologous recombination
|
CA2965509C
(en)
|
2014-10-24 |
2023-03-14 |
Avectas Limited |
Delivery across cell plasma membranes
|
CA2963820A1
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
PT3221457T
(pt)
|
2014-11-21 |
2019-06-27 |
Regeneron Pharma |
Métodos e composições para modificação genética visada através da utilização de arn guia emparelhados
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
CN105695485B
(zh)
*
|
2014-11-27 |
2020-02-21 |
中国科学院上海生命科学研究院 |
一种用于丝状真菌Crispr-Cas系统的Cas9编码基因及其应用
|
JP7068821B2
(ja)
|
2014-12-03 |
2022-05-17 |
アジレント・テクノロジーズ・インク |
化学修飾を有するガイドrna
|
KR102656470B1
(ko)
|
2014-12-10 |
2024-04-09 |
리전츠 오브 더 유니버스티 오브 미네소타 |
질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
|
WO2016094867A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Protected guide rnas (pgrnas)
|
EP3234111A1
(en)
|
2014-12-19 |
2017-10-25 |
Regeneron Pharmaceuticals, Inc. |
Stem cells for modeling type 2 diabetes
|
RU2707137C2
(ru)
|
2014-12-19 |
2019-11-22 |
Регенерон Фармасьютикалз, Инк. |
Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания
|
US11208638B2
(en)
|
2015-01-12 |
2021-12-28 |
The Regents Of The University Of California |
Heterodimeric Cas9 and methods of use thereof
|
WO2016123243A1
(en)
|
2015-01-28 |
2016-08-04 |
The Regents Of The University Of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
AU2016211118B2
(en)
*
|
2015-01-29 |
2022-03-31 |
Centre National De La Recherche Scientifique |
Method for inducing targeted meiotic recombinations
|
US11046952B2
(en)
*
|
2015-03-16 |
2021-06-29 |
The Broad Institute, Inc. |
Encoding of DNA vector identity via iterative hybridization detection of a barcode transcript
|
CN107567499A
(zh)
|
2015-03-27 |
2018-01-09 |
纳幕尔杜邦公司 |
大豆u6核小rna基因启动子及其在植物小rna基因的组成型表达中的用途
|
AU2016246450B2
(en)
|
2015-04-06 |
2022-03-17 |
Agilent Technologies, Inc. |
Chemically modified guide RNAs for CRISPR/Cas-mediated gene regulation
|
AU2016253150B2
(en)
|
2015-04-24 |
2022-04-21 |
Editas Medicine, Inc. |
Evaluation of Cas9 molecule/guide RNA molecule complexes
|
EP3294896A1
(en)
|
2015-05-11 |
2018-03-21 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
CN107614680A
(zh)
*
|
2015-05-14 |
2018-01-19 |
南加利福尼亚大学 |
利用重组核酸内切酶系统的最佳化基因编辑
|
JP2018516563A
(ja)
|
2015-05-29 |
2018-06-28 |
ノース カロライナ ステート ユニバーシティNorth Carolina State University |
Crispr核酸を用いて、細菌、古細菌、藻類、および、酵母をスクリーニングする方法
|
GB2543873A
(en)
|
2015-05-29 |
2017-05-03 |
Agenovir Corp |
Compositions and methods for cell targeted HPV treatment
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
EP3303634B1
(en)
|
2015-06-03 |
2023-08-30 |
The Regents of The University of California |
Cas9 variants and methods of use thereof
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
AU2016276702B2
(en)
|
2015-06-09 |
2022-07-28 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for improving transplantation
|
WO2016205276A1
(en)
|
2015-06-15 |
2016-12-22 |
North Carolina State University |
Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials
|
CN108290933A
(zh)
|
2015-06-18 |
2018-07-17 |
布罗德研究所有限公司 |
降低脱靶效应的crispr酶突变
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
WO2017004261A1
(en)
|
2015-06-29 |
2017-01-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
JP7044373B2
(ja)
|
2015-07-15 |
2022-03-30 |
ラトガース,ザ ステート ユニバーシティ オブ ニュージャージー |
ヌクレアーゼ非依存的な標的化遺伝子編集プラットフォームおよびその用途
|
EP4339287A3
(en)
|
2015-07-31 |
2024-05-22 |
Regents Of The University Of Minnesota |
Modified cells and methods of therapy
|
CA2995036A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Tunable endogenous protein degradation
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
CN108350449B
(zh)
|
2015-08-28 |
2022-05-31 |
通用医疗公司 |
工程化的CRISPR-Cas9核酸酶
|
US10526590B2
(en)
|
2015-08-31 |
2020-01-07 |
Agilent Technologies, Inc. |
Compounds and methods for CRISPR/Cas-based genome editing by homologous recombination
|
US20180251789A1
(en)
*
|
2015-09-04 |
2018-09-06 |
Massachusetts Institute Of Technology |
Multilayer genetic safety kill circuits based on single cas9 protein and multiple engineered grna in mammalian cells
|
US11261439B2
(en)
|
2015-09-18 |
2022-03-01 |
President And Fellows Of Harvard College |
Methods of making guide RNA
|
EP3352795B1
(en)
*
|
2015-09-21 |
2020-08-12 |
The Regents of The University of California |
Compositions and methods for target nucleic acid modification
|
AU2016326711B2
(en)
|
2015-09-24 |
2022-11-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve CRISPR/Cas-mediated genome editing
|
WO2017058751A1
(en)
|
2015-09-28 |
2017-04-06 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
JP7059468B2
(ja)
*
|
2015-10-08 |
2022-04-26 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
多重ゲノム編集
|
CN108513575A
(zh)
|
2015-10-23 |
2018-09-07 |
哈佛大学的校长及成员们 |
核碱基编辑器及其用途
|
US11111508B2
(en)
|
2015-10-30 |
2021-09-07 |
Brandeis University |
Modified CAS9 compositions and methods of use
|
GB2559526B
(en)
|
2015-11-03 |
2021-02-17 |
Harvard College |
Method and apparatus for volumetric imaging of a three-dimensional nucleic acid containing matrix
|
US11718858B2
(en)
|
2015-11-11 |
2023-08-08 |
Regents Of The University Of Minnesota |
Biocontainment/biocontrol system and methods
|
US11905521B2
(en)
|
2015-11-17 |
2024-02-20 |
The Chinese University Of Hong Kong |
Methods and systems for targeted gene manipulation
|
EP3377086B1
(en)
|
2015-11-19 |
2024-05-01 |
The Brigham and Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
WO2017112620A1
(en)
|
2015-12-22 |
2017-06-29 |
North Carolina State University |
Methods and compositions for delivery of crispr based antimicrobials
|
JP7449646B2
(ja)
|
2015-12-30 |
2024-03-14 |
アヴェクタス リミテッド |
細胞および組織への遺伝子編集タンパク質および組成物の、ベクターなしでの送達
|
KR20180095719A
(ko)
|
2016-01-11 |
2018-08-27 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
키메라 단백질 및 면역요법 방법
|
US9856497B2
(en)
|
2016-01-11 |
2018-01-02 |
The Board Of Trustee Of The Leland Stanford Junior University |
Chimeric proteins and methods of regulating gene expression
|
CN105624187A
(zh)
*
|
2016-02-17 |
2016-06-01 |
天津大学 |
酿酒酵母基因组定点突变的方法
|
US20190249172A1
(en)
|
2016-02-18 |
2019-08-15 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
US10538750B2
(en)
|
2016-02-29 |
2020-01-21 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by CRISPR proteins
|
JP2019515654A
(ja)
|
2016-03-16 |
2019-06-13 |
ザ ジェイ. デヴィッド グラッドストーン インスティテューツ |
肥満及び/又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物
|
EP3433362B1
(en)
|
2016-03-23 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Methods for enhancing the efficiency of gene editing
|
EP3433363A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
US11512311B2
(en)
|
2016-03-25 |
2022-11-29 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency
|
US11236313B2
(en)
|
2016-04-13 |
2022-02-01 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
KR102670601B1
(ko)
|
2016-04-19 |
2024-05-29 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신규한 crispr 효소 및 시스템
|
US11286478B2
(en)
|
2016-04-19 |
2022-03-29 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
CN116200465A
(zh)
|
2016-04-25 |
2023-06-02 |
哈佛学院董事及会员团体 |
用于原位分子检测的杂交链反应方法
|
EP3450570B1
(en)
*
|
2016-04-28 |
2021-03-10 |
Industry-Academic Cooperation Foundation, Yonsei University |
Method for evaluating, in vivo, activity of rna-guided nuclease in high-throughput manner
|
RU2021106817A
(ru)
|
2016-05-20 |
2021-04-06 |
Регенерон Фармасьютикалс, Инк. |
Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
|
EP3604527B1
(en)
|
2016-06-02 |
2021-05-12 |
Sigma-Aldrich Co., LLC |
Using programmable dna binding proteins to enhance targeted genome modification
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
AU2017280353B2
(en)
|
2016-06-24 |
2021-11-11 |
Inscripta, Inc. |
Methods for generating barcoded combinatorial libraries
|
CN109963564B
(zh)
*
|
2016-07-27 |
2022-08-12 |
利兰斯坦福初级大学董事会 |
用于核酸递送的解体型细胞穿透性复合物
|
CN109563505A
(zh)
*
|
2016-07-28 |
2019-04-02 |
帝斯曼知识产权资产管理有限公司 |
用于真核细胞的组装系统
|
CN109803530A
(zh)
|
2016-07-29 |
2019-05-24 |
瑞泽恩制药公司 |
包含引起c-截短的原纤维蛋白-1表达的突变的小鼠
|
BR112019001887A2
(pt)
|
2016-08-02 |
2019-07-09 |
Editas Medicine Inc |
composições e métodos para o tratamento de doença associada a cep290
|
WO2018027078A1
(en)
|
2016-08-03 |
2018-02-08 |
President And Fellows Of Harard College |
Adenosine nucleobase editors and uses thereof
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
WO2018049009A2
(en)
*
|
2016-09-07 |
2018-03-15 |
Sangamo Therapeutics, Inc. |
Modulation of liver genes
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
AU2017335890B2
(en)
|
2016-09-30 |
2024-05-09 |
The Regents Of The University Of California |
RNA-guided nucleic acid modifying enzymes and methods of use thereof
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
KR20240064734A
(ko)
|
2016-10-14 |
2024-05-13 |
더 제너럴 하스피탈 코포레이션 |
후성적으로 조절되는 부위-특이적 뉴클레아제
|
KR20240007715A
(ko)
|
2016-10-14 |
2024-01-16 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
EP3529359B1
(en)
|
2016-10-18 |
2023-12-13 |
Regents of the University of Minnesota |
Tumor infiltrating lymphocytes for use in therapy
|
EP3541408A4
(en)
|
2016-11-15 |
2020-06-24 |
The Schepens Eye Research Institute, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS
|
AU2017378427A1
(en)
|
2016-12-14 |
2019-06-20 |
Ligandal, Inc. |
Methods and compositions for nucleic acid and protein payload delivery
|
EP4095228A1
(en)
|
2016-12-22 |
2022-11-30 |
Avectas Limited |
System for vector-free intracellular delivery by reversible permeabilisation
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
EP3565608A4
(en)
|
2017-01-05 |
2020-12-16 |
Rutgers, The State University of New Jersey |
TARGETED GENEDITATION PLATFORM INDEPENDENT OF DNA DOUBLE STRAND BREAKAGE AND USES THEREOF
|
RU2021133626A
(ru)
|
2017-01-23 |
2022-01-31 |
Регенерон Фармасьютикалз, Инк. |
Варианты hsd17b13 и их применения
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
EP4119552A1
(en)
|
2017-02-08 |
2023-01-18 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
SG11201908658TA
(en)
|
2017-03-23 |
2019-10-30 |
Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
US20210115407A1
(en)
|
2017-04-12 |
2021-04-22 |
The Broad Institute, Inc. |
Respiratory and sweat gland ionocytes
|
WO2018195129A1
(en)
|
2017-04-17 |
2018-10-25 |
University Of Maryland, College Park |
Embryonic cell cultures and methods of using the same
|
WO2018195545A2
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
WO2018195486A1
(en)
|
2017-04-21 |
2018-10-25 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
WO2018201086A1
(en)
|
2017-04-28 |
2018-11-01 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
WO2018209014A1
(en)
|
2017-05-10 |
2018-11-15 |
Regents Of The University Of Minnesota |
Programmable transcription factors and methods
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
CN110997728A
(zh)
|
2017-05-25 |
2020-04-10 |
通用医疗公司 |
二分型碱基编辑器(bbe)结构和ii-型-cas9锌指编辑
|
EP3635112A2
(en)
|
2017-06-06 |
2020-04-15 |
Zymergen, Inc. |
A htp genomic engineering platform for improving fungal strains
|
US20200370058A1
(en)
|
2017-06-06 |
2020-11-26 |
Zymergen Inc. |
A htp genomic engineering platform for improving escherichia coli
|
US20200149041A1
(en)
*
|
2017-06-07 |
2020-05-14 |
The University Of Tokyo |
Gene Therapy Drug for Granular Corneal Degeneration
|
WO2018227114A1
(en)
|
2017-06-09 |
2018-12-13 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
AU2018283405A1
(en)
|
2017-06-15 |
2020-01-16 |
The Regents Of The University Of California |
Targeted non-viral DNA insertions
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
JP2020530307A
(ja)
|
2017-06-30 |
2020-10-22 |
インティマ・バイオサイエンス,インコーポレーテッド |
遺伝子治療のためのアデノ随伴ウイルスベクター
|
EP3652312A1
(en)
|
2017-07-14 |
2020-05-20 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
US20190032156A1
(en)
|
2017-07-31 |
2019-01-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for assessing crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
|
SG11201912235PA
(en)
|
2017-07-31 |
2020-01-30 |
Regeneron Pharma |
Cas-transgenic mouse embryonic stem cells and mice and uses thereof
|
MX2020001177A
(es)
|
2017-07-31 |
2020-09-25 |
Regeneron Pharma |
Animales no humanos reporteros de crispr y usos de los mismos.
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
IL311278A
(en)
|
2017-09-29 |
2024-05-01 |
Intellia Therapeutics Inc |
Polynucleotides, preparations, and methods for genome editing
|
MX2020003589A
(es)
|
2017-09-29 |
2020-07-22 |
Regeneron Pharma |
Animales no humanos que comprenden un locus ttr humanizado y metodos de uso.
|
PT3688162T
(pt)
|
2017-09-29 |
2024-04-23 |
Intellia Therapeutics Inc |
Formulações
|
JP2021500864A
(ja)
|
2017-09-29 |
2021-01-14 |
インテリア セラピューティクス,インコーポレイテッド |
Ttr遺伝子編集およびattrアミロイドーシスの治療用の組成物および方法
|
JP2020537541A
(ja)
|
2017-09-29 |
2020-12-24 |
インテリア セラピューティクス,インコーポレーテッド |
脂質ナノ粒子を用いるインビトロでのmrnaの送達方法
|
CN111757937A
(zh)
|
2017-10-16 |
2020-10-09 |
布罗德研究所股份有限公司 |
腺苷碱基编辑器的用途
|
KR102503130B1
(ko)
|
2017-10-27 |
2023-02-24 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
내인성 t 세포 수용체의 표적화된 대체
|
AU2018369784B2
(en)
|
2017-11-14 |
2023-06-01 |
Massachusetts Eye And Ear Infirmary |
RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
|
AU2019207409B2
(en)
|
2018-01-12 |
2023-02-23 |
Basf Se |
Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
|
US20190233816A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
CA3089331A1
(en)
|
2018-03-19 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
BR112020021229A2
(pt)
|
2018-04-19 |
2021-02-02 |
The Regents Of The University Of California |
composições e métodos para edição de genes
|
EP3794130A4
(en)
|
2018-05-16 |
2022-07-27 |
Synthego Corporation |
METHODS AND SYSTEMS FOR DESIGN AND USE OF GUIDE RNA
|
US20210261901A1
(en)
|
2018-06-01 |
2021-08-26 |
Avectas Limited |
Cell engineering platform
|
JP2021530212A
(ja)
|
2018-07-13 |
2021-11-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
レトロトランスポゾンベースの送達媒体及びその使用方法
|
SG11202102068TA
(en)
|
2018-07-31 |
2021-03-30 |
Broad Inst Inc |
Novel crispr enzymes and systems
|
WO2020028327A1
(en)
|
2018-07-31 |
2020-02-06 |
Intellia Therapeutics, Inc. |
Compositions and methods for hydroxyacid oxidase 1 ( hao1) gene editing for treating primary hyperoxaluria type 1 (ph1)
|
WO2020037490A1
(en)
*
|
2018-08-21 |
2020-02-27 |
Institute Of Hematology And Blood Diseases Hospital, Cams & Pumc |
Method of genome editing in mammalian stem cell
|
KR20210086621A
(ko)
|
2018-09-28 |
2021-07-08 |
인텔리아 테라퓨틱스, 인크. |
락테이트 데히드로게나제 (ldha) 유전자 편집을 위한 조성물 및 방법
|
EP3861120A4
(en)
|
2018-10-01 |
2023-08-16 |
North Carolina State University |
RECOMBINANT TYPE I CRISPR-CAS SYSTEM
|
BR112021007025A2
(pt)
|
2018-10-16 |
2021-08-03 |
Intellia Therapeutics, Inc. |
composições e métodos para imunoterapia
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
WO2020092704A1
(en)
|
2018-10-31 |
2020-05-07 |
Zymergen Inc. |
Multiplexed deterministic assembly of dna libraries
|
WO2020089448A1
(en)
*
|
2018-11-01 |
2020-05-07 |
Keygene N.V. |
Dual guide rna for crispr/cas genome editing in plants cells
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
KR20200071198A
(ko)
|
2018-12-10 |
2020-06-19 |
네오이뮨텍, 인코퍼레이티드 |
Nrf2 발현 조절 기반 T 세포 항암면역치료법
|
EP3894550A4
(en)
|
2018-12-14 |
2023-01-04 |
Pioneer Hi-Bred International, Inc. |
NEW CRISPR-CAS SYSTEMS FOR GENOME EDITING
|
AU2019403015B2
(en)
|
2018-12-20 |
2024-01-18 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated repeat expansion
|
US20220106584A1
(en)
|
2019-01-14 |
2022-04-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
EP3921417A4
(en)
|
2019-02-04 |
2022-11-09 |
The General Hospital Corporation |
ADENINE DNA BASE EDITOR VARIANTS WITH REDUCED OFF-TARGET RNA EDITING
|
US20220145330A1
(en)
|
2019-02-10 |
2022-05-12 |
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads |
Modified mitochondrion and methods of use thereof
|
EP4219700A1
(en)
|
2019-03-07 |
2023-08-02 |
The Regents of the University of California |
Crispr-cas effector polypeptides and methods of use thereof
|
US11053515B2
(en)
|
2019-03-08 |
2021-07-06 |
Zymergen Inc. |
Pooled genome editing in microbes
|
KR20210136997A
(ko)
|
2019-03-08 |
2021-11-17 |
지머젠 인코포레이티드 |
미생물에서 반복적 게놈 편집
|
ES2970541T3
(es)
|
2019-03-18 |
2024-05-29 |
Regeneron Pharma |
Plataforma de cribado CRISPR/CAS para identificar modificadores genéticos de la siembra o agregación de tau
|
AU2020241856B2
(en)
|
2019-03-18 |
2024-06-27 |
Regeneron Pharmaceuticals, Inc. |
CRISPR/Cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
|
DE112020001342T5
(de)
|
2019-03-19 |
2022-01-13 |
President and Fellows of Harvard College |
Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
|
CA3134544A1
(en)
|
2019-03-28 |
2020-10-01 |
Intellia Therapeutics, Inc. |
Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof
|
EP3947670A2
(en)
|
2019-03-28 |
2022-02-09 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for polypeptide expression
|
MX2021011565A
(es)
|
2019-03-28 |
2021-11-12 |
Intellia Therapeutics Inc |
Composiciones y métodos que comprenden un arn guía de ttr y un polinucleótido que codifica un agente de fijacion a adn guiado por arn.
|
KR20210148154A
(ko)
|
2019-04-03 |
2021-12-07 |
리제너론 파마슈티칼스 인코포레이티드 |
세이프 하버 좌위 내로의 항체 코딩 서열의 삽입을 위한 방법 및 조성물
|
WO2020206134A1
(en)
|
2019-04-04 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for scarless introduction of targeted modifications into targeting vectors
|
CA3133360A1
(en)
|
2019-04-04 |
2020-10-08 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized coagulation factor 12 locus
|
US11891618B2
(en)
|
2019-06-04 |
2024-02-06 |
Regeneron Pharmaceuticals, Inc. |
Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
|
AU2020289581A1
(en)
|
2019-06-07 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized albumin locus
|
JP2022536606A
(ja)
|
2019-06-14 |
2022-08-18 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
タウオパチーのモデル
|
AU2020337919A1
(en)
|
2019-08-27 |
2022-03-24 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of disorders associated with repetitive DNA
|
CN114616002A
(zh)
|
2019-09-13 |
2022-06-10 |
瑞泽恩制药公司 |
使用由脂质纳米颗粒递送的crispr/cas系统在动物中进行的转录调控
|
US20230025039A1
(en)
|
2019-09-20 |
2023-01-26 |
The Broad Institute, Inc. |
Novel type vi crispr enzymes and systems
|
IL292605A
(en)
|
2019-11-08 |
2022-07-01 |
Regeneron Pharma |
CRISPR and AAV strategies for the treatment of x-linked childhood retinoschisis
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
EP4064830A1
(en)
|
2019-11-29 |
2022-10-05 |
Basf Se |
Increasing resistance against fungal infections in plants
|
KR20220116504A
(ko)
|
2019-12-19 |
2022-08-23 |
바스프 에스이 |
정밀 화학물의 제조에서 공시 수율, 탄소-전환-효율 및 탄소 기질 적응성의 증가
|
CN115135762A
(zh)
|
2019-12-20 |
2022-09-30 |
巴斯夫欧洲公司 |
降低萜烯的毒性和增加微生物的生产潜力
|
US11060141B1
(en)
|
2019-12-23 |
2021-07-13 |
Stilla Technologies |
Multiplex drop-off digital polymerase chain reaction methods
|
EP4100528A1
(en)
*
|
2020-02-07 |
2022-12-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for kallikrein (klkb1) gene editing
|
EP4114946A1
(en)
|
2020-03-04 |
2023-01-11 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for sensitization of tumor cells to immune therapy
|
WO2021191678A1
(en)
|
2020-03-23 |
2021-09-30 |
Avectas Limited |
Engineering of dendritic cells for generation of vaccines against sars-cov-2
|
WO2021195079A1
(en)
|
2020-03-23 |
2021-09-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
US20210319851A1
(en)
|
2020-04-03 |
2021-10-14 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
EP4133069A2
(en)
|
2020-04-08 |
2023-02-15 |
Astrazeneca AB |
Compositions and methods for improved site-specific modification
|
AU2021263745A1
(en)
|
2020-04-28 |
2022-12-08 |
Intellia Therapeutics, Inc. |
Methods of in vitro cell delivery
|
EP4146804A1
(en)
|
2020-05-08 |
2023-03-15 |
The Broad Institute Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
WO2022008935A1
(en)
|
2020-07-10 |
2022-01-13 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
TW202218686A
(zh)
|
2020-09-09 |
2022-05-16 |
美商維泰克斯製藥公司 |
用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之組合物及方法
|
EP4222167A1
(en)
|
2020-09-30 |
2023-08-09 |
Nobell Foods, Inc. |
Recombinant milk proteins and food compositions comprising the same
|
US10947552B1
(en)
|
2020-09-30 |
2021-03-16 |
Alpine Roads, Inc. |
Recombinant fusion proteins for producing milk proteins in plants
|
US10894812B1
(en)
|
2020-09-30 |
2021-01-19 |
Alpine Roads, Inc. |
Recombinant milk proteins
|
AU2021364781A1
(en)
|
2020-10-21 |
2023-06-01 |
Massachusetts Institute Of Technology |
Systems, methods, and compositions for site-specific genetic engineering using programmable addition via site-specific targeting elements (paste)
|
EP4240854A1
(en)
|
2020-11-06 |
2023-09-13 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of dm1 with slucas9 and sacas9
|
WO2022120022A1
(en)
|
2020-12-02 |
2022-06-09 |
Regeneron Pharmaceuticals, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
TW202235617A
(zh)
|
2020-12-11 |
2022-09-16 |
美商英特利亞醫療公司 |
用於減少細胞中ii類mhc之組合物及方法
|
CR20230320A
(es)
|
2020-12-23 |
2023-10-23 |
Intellia Therapeutics Inc |
Composiciones y métodos para reducir los hla-a en una célula
|
MX2023007465A
(es)
|
2020-12-23 |
2023-08-18 |
Intellia Therapeutics Inc |
Composiciones y metodos para modificar geneticamente ciita en una celula.
|
WO2022148955A1
(en)
|
2021-01-05 |
2022-07-14 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
JP2024505084A
(ja)
|
2021-02-01 |
2024-02-02 |
アヴェクタス リミテッド |
送達プラットフォーム
|
JP2024505678A
(ja)
|
2021-02-08 |
2024-02-07 |
インテリア セラピューティクス,インコーポレイテッド |
免疫療法のためのリンパ球活性化遺伝子3(lag3)組成物及び方法
|
WO2022170193A2
(en)
|
2021-02-08 |
2022-08-11 |
Intellia Therapeutics, Inc. |
T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy
|
WO2022170172A1
(en)
|
2021-02-08 |
2022-08-11 |
Intellia Therapeutics, Inc. |
Natural killer cell receptor 2b4 compositions and methods for immunotherapy
|
WO2022182959A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
|
EP4298222A1
(en)
|
2021-02-26 |
2024-01-03 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9
|
US20220331361A1
(en)
*
|
2021-04-07 |
2022-10-20 |
Century Therapeutics, Inc. |
Gene transfer vectors and methods of engineering cells
|
WO2022214522A2
(en)
|
2021-04-07 |
2022-10-13 |
Astrazeneca Ab |
Compositions and methods for site-specific modification
|
AU2022258733A1
(en)
|
2021-04-17 |
2023-11-30 |
Intellia Therapeutics, Inc. |
Inhibitors of dna-dependent protein kinase and compositions and uses thereof
|
BR112023021445A2
(pt)
|
2021-04-17 |
2024-01-23 |
Intellia Therapeutics Inc |
Composições de nanopartículas lipídicas
|
EP4322920A1
(en)
|
2021-04-17 |
2024-02-21 |
Intellia Therapeutics, Inc. |
Lipid nanoparticle compositions
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
CA3218511A1
(en)
|
2021-05-10 |
2022-11-17 |
Sqz Biotechnologies Company |
Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
|
WO2022251644A1
(en)
|
2021-05-28 |
2022-12-01 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
WO2022256437A1
(en)
|
2021-06-02 |
2022-12-08 |
Lyell Immunopharma, Inc. |
Nr4a3-deficient immune cells and uses thereof
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
WO2023028471A1
(en)
|
2021-08-24 |
2023-03-02 |
Intellia Therapeutics, Inc. |
Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy
|
WO2023039444A2
(en)
|
2021-09-08 |
2023-03-16 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
WO2023039586A1
(en)
|
2021-09-10 |
2023-03-16 |
Agilent Technologies, Inc. |
Guide rnas with chemical modification for prime editing
|
CN118119707A
(zh)
|
2021-09-30 |
2024-05-31 |
阿斯利康(瑞典)有限公司 |
抑制剂增加CRISPR/Cas插入效率的用途
|
CN118119702A
(zh)
|
2021-10-14 |
2024-05-31 |
隆萨销售股份有限公司 |
用于细胞外囊泡产生的经修饰的生产者细胞
|
CN118251491A
(zh)
|
2021-10-28 |
2024-06-25 |
瑞泽恩制药公司 |
用于敲除C5的CRISPR/Cas相关方法及组合物
|
IL312452A
(en)
|
2021-11-01 |
2024-06-01 |
Tome Biosciences Inc |
A transformant has a single structure for the simultaneous transfer of a gene editing mechanism and a nucleic acid cargo
|
CA3237482A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
CA3237303A1
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
WO2023081200A2
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
WO2023108047A1
(en)
|
2021-12-08 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
WO2023150620A1
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Crispr-mediated transgene insertion in neonatal cells
|
WO2023172926A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
TW202345911A
(zh)
|
2022-03-08 |
2023-12-01 |
美商維泰克斯製藥公司 |
用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之部分外顯子44、50及53之精確切除
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
WO2023212677A2
(en)
|
2022-04-29 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Identification of tissue-specific extragenic safe harbors for gene therapy approaches
|
WO2023220603A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Vectors and methods for in vivo antibody production
|
WO2023225665A1
(en)
|
2022-05-19 |
2023-11-23 |
Lyell Immunopharma, Inc. |
Polynucleotides targeting nr4a3 and uses thereof
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
WO2023235726A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr interference therapeutics for c9orf72 repeat expansion disease
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
WO2024020346A2
(en)
|
2022-07-18 |
2024-01-25 |
Renagade Therapeutics Management Inc. |
Gene editing components, systems, and methods of use
|
WO2024020352A1
(en)
|
2022-07-18 |
2024-01-25 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
WO2024031053A1
(en)
|
2022-08-05 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Aggregation-resistant variants of tdp-43
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
WO2024064952A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells overexpressing c-jun
|
WO2024064958A1
(en)
|
2022-09-23 |
2024-03-28 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
WO2024077174A1
(en)
|
2022-10-05 |
2024-04-11 |
Lyell Immunopharma, Inc. |
Methods for culturing nr4a-deficient cells
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
WO2024102434A1
(en)
|
2022-11-10 |
2024-05-16 |
Senda Biosciences, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
US20240173426A1
(en)
|
2022-11-14 |
2024-05-30 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
WO2024137766A2
(en)
|
2022-12-21 |
2024-06-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for proprotein convertase subtilisin kexin 9 (pcsk9) editing
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|